Drug Trial Radar · NCT05954988
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
Last checked: Nov 19, 2026Latest source record: Jul 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jul 6, 2023
Primary completion
Sep 25, 2024
Study completion Sep 25, 2024
Sponsor
- Lead sponsor
- Rein TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
LTI-03Drug
Caveolin-1-Scaffolding-Protein-Derived Peptide
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse Events (TEAEs)Time frame: 21 days (dosing x 14 days; follow up x 7 days)
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
University of Southern California
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
Agaplesion Evangelisches Krankenhaus Mittelhessen
Giessen, Germany
University of Edinburgh
Edinburgh, United Kingdom
Royal Brompton Hospital
London, United Kingdom
Royal Victoria Infirmary
Newcastle, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.